Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortés, Chris Twelves, Han Koh et al.|The Lancet|2011Cited by 1.1k
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysCharlotte Benson, Chris Twelves|British Journal of Cancer|2006Cited by 257
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Clinical Cancer Research|2014Cited by 47
Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid ModelsMaria Jové, Chris Twelves|Journal of Pharmacology and Experimental Therapeutics|2019Cited by 11
Data from First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Unknown|2023Cited by 0